重组小鼠抑瘤素M/Murine OSM 现货重组小鼠抑瘤素M/Murine OSM 现货重组小鼠抑瘤素M/Murine OSM 现货重组小鼠抑瘤素M/Murine OSM 现货
Recombinant Murine Oncostatin-M

本公司代理的PrimeGene细胞因子、趋化蛋白、激素、酶、泛素等均有现货销售，货期短，质量保证！

• 技术参数
• FAQs

技术参数

技术参数技术参数

FAQs

FAQsFAQs

Synonyms

Synonyms

Synonyms

Accession

P53347

Accession

Accession

P53347

P53347P53347

GeneID

18413

GeneID

GeneID

18413

1841318413

Source

Escherichia coli.

Source

Source

Escherichia coli.

Escherichia coli.

Molecular Weight

Approximately 20.4 kDa, a single non-glycosylated polypeptide chain containing 181 amino acids.

Molecular Weight

Molecular Weight

Approximately 20.4 kDa, a single non-glycosylated polypeptide chain containing 181 amino acids.

Approximately 20.4 kDa, a single non-glycosylated polypeptide chain containing 181 amino acids.

AA Sequence

NRGCSNSSSQ LLSQLQNQAN LTGNTESLLE PYIRLQNLNT PDLRAACTQH SVAFPSEDTL RQLSKPHFLS TVYTTLDRVL YQLDALRQKF LKTPAFPKLD SARHNILGIR NNVFCMARLL NHSLEIPEPT QTDSGASRST TTPDVFNTKI GSCGFLWGYH RFMGSVGRVF REWDDGSTRS R

AA Sequence

AA Sequence

NRGCSNSSSQ LLSQLQNQAN LTGNTESLLE PYIRLQNLNT PDLRAACTQH SVAFPSEDTL RQLSKPHFLS TVYTTLDRVL YQLDALRQKF LKTPAFPKLD SARHNILGIR NNVFCMARLL NHSLEIPEPT QTDSGASRST TTPDVFNTKI GSCGFLWGYH RFMGSVGRVF REWDDGSTRS R

NRGCSNSSSQ LLSQLQNQAN LTGNTESLLE PYIRLQNLNT PDLRAACTQH SVAFPSEDTL RQLSKPHFLS TVYTTLDRVL YQLDALRQKF LKTPAFPKLD SARHNILGIR NNVFCMARLL NHSLEIPEPT QTDSGASRST TTPDVFNTKI GSCGFLWGYH RFMGSVGRVF REWDDGSTRS R

Purity

> 96 % by SDS-PAGE and HPLC analyses.

Purity

Purity

> 96 % by SDS-PAGE and HPLC analyses.

> 96 % by SDS-PAGE and HPLC analyses.

Biological Activity

Fully biologically active when compared to standard. The ED₅₀ as determined by a cell proliferation assay using murine NIH-3T3 cells is less than 1.0 ng/ml, corresponding to a specific activity of > 1.0 × 10⁶ IU/mg.

Biological Activity

Biological Activity

Fully biologically active when compared to standard. The ED₅₀ as determined by a cell proliferation assay using murine NIH-3T3 cells is less than 1.0 ng/ml, corresponding to a specific activity of > 1.0 × 10⁶ IU/mg.

Fully biologically active when compared to standard. The ED₅₀50 as determined by a cell proliferation assay using murine NIH-3T3 cells is less than 1.0 ng/ml, corresponding to a specific activity of > 1.0 × 10⁶6 IU/mg.

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Physical Appearance

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation

Lyophilized from a 0.2 μm filtered concentrated solution in 2 × PBS, pH 7.4, 5 % trehalose.

Formulation

Formulation

Lyophilized from a 0.2 μm filtered concentrated solution in 2 × PBS, pH 7.4, 5 % trehalose.

Lyophilized from a 0.2 μm filtered concentrated solution in 2 × PBS, pH 7.4, 5 % trehalose.

Endotoxin

Less than 1 EU/μg of rMuOSM as determined by LAL method.

Endotoxin

Endotoxin

Less than 1 EU/μg of rMuOSM as determined by LAL method.

Less than 1 EU/μg of rMuOSM as determined by LAL method.

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Reconstitution

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Stability & Storage

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Usage

NOT FOR HUMAN USE.

Usage

Usage

NOT FOR HUMAN USE.

NOT FOR HUMAN USE.

SDS-PAGE

SDS-PAGE

SDS-PAGE

Reference

1. Tanaka M, Miyajima A. 2003. Rev Physiol Biochem Pharmacol. 149:39-52.
2. Mosley B, De Imus C, Friend D, et al. 1996. J Biol Chem. 271:32635-43.
3. Malik N, Kallestad JC, Gunderson NL, et al. 1989. Mol Cell Biol. 9:2847-53.
4. Brown TJ, Rowe JM, Liu JW, et al. 1991. J Immunol. 147:2175-80.

Reference

Reference

1. Tanaka M, Miyajima A. 2003. Rev Physiol Biochem Pharmacol. 149:39-52.
2. Mosley B, De Imus C, Friend D, et al. 1996. J Biol Chem. 271:32635-43.
3. Malik N, Kallestad JC, Gunderson NL, et al. 1989. Mol Cell Biol. 9:2847-53.
4. Brown TJ, Rowe JM, Liu JW, et al. 1991. J Immunol. 147:2175-80.

1. Tanaka M, Miyajima A. 2003. Rev Physiol Biochem Pharmacol. 149:39-52.
2. Mosley B, De Imus C, Friend D, et al. 1996. J Biol Chem. 271:32635-43.
3. Malik N, Kallestad JC, Gunderson NL, et al. 1989. Mol Cell Biol. 9:2847-53.
4. Brown TJ, Rowe JM, Liu JW, et al. 1991. J Immunol. 147:2175-80.

background

Oncostatin M (OSM) is a multifunctional cytokine that belongs to the Interleukin-6 subfamily. Among the family members, OSM is most closely related to leukemia inhibitory factor (LIF) and it in fact utilizes the LIF receptor in addition to its specific receptor in the human. A biologically active OSM receptor has been previously described that consists of a heterodimer of leukemia inhibitory factor receptor (LIFR) and gp130. OSM is synthesized by stimulated T-cells and monocytes. Furthermore, the effects of OSM on endothelial cells suggest a pro-inflammatory role for OSM and endothelial cells possess a large number of OSM receptors. Recombinant murine OSM contains 181 amino acids and has a molecular mass of 20.4 kDa. It has approximately 48 % and 72 % amino acid sequence identity with human and rat OSM.

background

background

Oncostatin M (OSM) is a multifunctional cytokine that belongs to the Interleukin-6 subfamily. Among the family members, OSM is most closely related to leukemia inhibitory factor (LIF) and it in fact utilizes the LIF receptor in addition to its specific receptor in the human. A biologically active OSM receptor has been previously described that consists of a heterodimer of leukemia inhibitory factor receptor (LIFR) and gp130. OSM is synthesized by stimulated T-cells and monocytes. Furthermore, the effects of OSM on endothelial cells suggest a pro-inflammatory role for OSM and endothelial cells possess a large number of OSM receptors. Recombinant murine OSM contains 181 amino acids and has a molecular mass of 20.4 kDa. It has approximately 48 % and 72 % amino acid sequence identity with human and rat OSM.

Oncostatin M (OSM) is a multifunctional cytokine that belongs to the Interleukin-6 subfamily. Among the family members, OSM is most closely related to leukemia inhibitory factor (LIF) and it in fact utilizes the LIF receptor in addition to its specific receptor in the human. A biologically active OSM receptor has been previously described that consists of a heterodimer of leukemia inhibitory factor receptor (LIFR) and gp130. OSM is synthesized by stimulated T-cells and monocytes. Furthermore, the effects of OSM on endothelial cells suggest a pro-inflammatory role for OSM and endothelial cells possess a large number of OSM receptors. Recombinant murine OSM contains 181 amino acids and has a molecular mass of 20.4 kDa. It has approximately 48 % and 72 % amino acid sequence identity with human and rat OSM.